CA
NZ
UK
AU
IND
US
…
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Income before tax | -94.62M | -51.16M | -26.52M | -5.10M |
| Net income | -87.46M | -50.07M | -26.38M | -4.65M |
| Selling general administrative | 30.64M | 15.20M | 5.57M | 3.61M |
| Reconciled depreciation | 1.90M | 1.12M | 0.33M | 0.10M |
| Ebit | -99.14M | -52.24M | -26.67M | -11.82M |
| Ebitda | -97.25M | -51.13M | -26.34M | -11.72M |
| Depreciation and amortization | 1.90M | 1.12M | 0.33M | 0.10M |
| Non operating income net other | - | -0.03M | - | - |
| Operating income | -97.25M | -51.13M | -26.67M | -11.82M |
| Other operating expenses | 97.25M | 51.13M | 26.67M | 11.82M |
| Interest expense | 2.63M | 0.03M | 0.00M | 0.00M |
| Interest income | 2.63M | - | 0.14M | 0.45M |
| Net interest income | 2.63M | -0.03M | 0.14M | 0.45M |
| Income tax expense | -7.16M | -1.09M | -0.14M | -0.45M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 97.25M | 51.13M | 26.67M | 11.82M |
| Total other income expense net | 2.63M | -0.03M | 0.14M | 6.72M |
| Net income from continuing ops | -94.62M | -51.16M | -26.52M | -5.10M |
| Net income applicable to common shares | -94.62M | -51.16M | -26.52M | -5.10M |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 469.19M | 252.06M | 305.83M | 43.53M | 18.24M |
| Other current assets | 10.22M | 21.16M | 7.64M | 0.90M | 0.59M |
| Total liab | 226.83M | 39.50M | 7.12M | 85.02M | 33.76M |
| Total stockholder equity | 242.36M | 212.55M | 298.72M | -41.49M | -15.52M |
| Other current liab | 15.35M | 7.58M | 6.01M | 1.76M | 1.21M |
| Common stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -194.97M | -188.28M | -93.67M | -42.51M | -15.99M |
| Other liab | - | - | 0.40M | - | 0.02M |
| Other assets | 0.00M | 9.16M | 305.83M | 0.54M | - |
| Cash | 67.60M | 45.16M | 291.06M | 39.05M | 16.84M |
| Total current liabilities | 158.80M | 21.97M | 6.72M | 3.36M | 1.92M |
| Current deferred revenue | 132.26M | - | - | - | - |
| Net debt | 0.63M | -19.22M | -291.06M | -39.05M | -16.84M |
| Short term debt | 7.91M | 8.41M | - | - | - |
| Short long term debt total | 68.23M | 25.94M | - | - | - |
| Other stockholder equity | 437.13M | 402.89M | 392.38M | 1.02M | 0.47M |
| Property plant equipment | - | 33.02M | 6.26M | 3.04M | 0.80M |
| Total current assets | 369.77M | 209.88M | 298.70M | 39.95M | 17.44M |
| Net tangible assets | - | 212.55M | 298.72M | -41.49M | -15.52M |
| Short term investments | 284.37M | 143.56M | - | - | - |
| Net receivables | 7.58M | - | 0.87M | - | - |
| Inventory | 0.00M | - | - | - | - |
| Accounts payable | 3.28M | 5.99M | 0.71M | 1.60M | 0.71M |
| Accumulated other comprehensive income | 0.20M | -2.06M | -305.83M | - | - |
| Common stock total equity | - | - | 0.00M | - | - |
| Retained earnings total equity | - | - | -93.67M | - | - |
| Non currrent assets other | 2.79M | 9.16M | 0.87M | 0.54M | - |
| Non current assets total | 99.42M | 42.18M | 7.13M | 3.58M | 0.80M |
| Capital lease obligations | 68.23M | 25.94M | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Investments | -148.65M | -4.58M | -2.32M | -0.63M |
| Change to liabilities | 5.29M | 3.25M | 0.63M | 0.37M |
| Total cashflows from investing activities | -148.65M | -4.58M | -2.32M | -0.63M |
| Total cash from financing activities | 0.48M | 307.46M | 50.09M | 0.04M |
| Change to operating activities | -16.40M | -2.71M | -0.35M | -0.19M |
| Net income | -94.62M | -51.16M | -26.52M | -5.10M |
| Change in cash | -241.96M | 252.02M | 22.20M | -11.39M |
| Begin period cash flow | 291.06M | 39.05M | 16.84M | 28.24M |
| End period cash flow | 49.11M | 291.06M | 39.05M | 16.84M |
| Total cash from operating activities | -93.79M | -50.86M | -25.57M | -10.80M |
| Issuance of capital stock | 0.00M | 306.52M | 49.84M | 0.00M |
| Depreciation | 1.90M | 1.12M | 0.33M | 0.10M |
| Sale purchase of stock | 0.28M | 191.10M | - | - |
| Other cashflows from financing activities | -148.65M | 116.77M | -2.32M | -0.63M |
| Change to netincome | 10.05M | 2.60M | 0.34M | -5.98M |
| Capital expenditures | 2.89M | 4.58M | 2.33M | 0.63M |
| Cash flows other operating | - | -6.67M | - | - |
| Cash and cash equivalents changes | - | 252.02M | - | - |
| Change in working capital | -11.11M | -3.42M | 0.28M | 0.17M |
| Stock based compensation | 9.89M | 2.53M | 0.33M | 0.29M |
| Other non cash items | 0.15M | 0.07M | 0.02M | -6.27M |
| Free cash flow | -96.67M | -55.44M | -27.89M | -11.43M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics Inc |
0.34 7.47% |
4.89 | 21.81 | - | 3.37 | 1.80 | 1.18 | -472.68 |
| NVO Novo Nordisk A/S |
0.01 0.02% |
40.31 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
4.59 0.85% |
547.09 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
1.45 0.16% |
904.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
One Design Center Place, Boston, MA, United States, 02210
(857) 520-9158
160
| Name | Title | Year Born |
|---|---|---|
| Mr. Dipal Doshi | Pres, CEO & Director | 1976 |
| Mr. Nathan J. Dowden | Chief Operating Officer | 1971 |
| Dr. Natarajan Sethuraman Ph.D. | Chief Scientific Officer | 1962 |
| Mr. Kory James Wentworth CPA | CFO & Treasurer | 1980 |
| Dr. Jared Cohen J.D., Ph.D. | Gen. Counsel | NA |
| Ms. Kerry Robert M.S. | VP of People | NA |
| Dr. Nerissa C. Kreher M.B.A., M.D., M.S. | Chief Medical Officer | 1973 |
| Ms. Karla MacDonald | Chief Corp. Affairs Officer | NA |
| Mr. Dipal Doshi | CEO & Director | 1976 |
| Mr. Nathan J. Dowden | President & COO | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...